These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 17404086)

  • 1. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
    Wu CY; Wu MS; Chiang EP; Chen YJ; Chen CJ; Chi NH; Shih YT; Chen GH; Lin JT
    Clin Cancer Res; 2007 Apr; 13(7):2054-60. PubMed ID: 17404086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
    Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
    Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
    Wang CS; Wu TL; Tsao KC; Sun CF
    Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of matrix metalloproteinase-9 protein polymorphisms with lymph node metastasis but not invasion of gastric cancer.
    Tang Y; Zhu J; Chen L; Chen L; Zhang S; Lin J
    Clin Cancer Res; 2008 May; 14(9):2870-7. PubMed ID: 18451255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma.
    Hayasaka A; Suzuki N; Fujimoto N; Iwama S; Fukuyama E; Kanda Y; Saisho H
    Hepatology; 1996 Nov; 24(5):1058-62. PubMed ID: 8903375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer.
    Tamura M; Oda M; Matsumoto I; Tsunezuka Y; Kawakami K; Ohta Y; Watanabe G
    Ann Surg Oncol; 2004 Oct; 11(10):928-33. PubMed ID: 15383417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum matrix metalloproteinase-9 level associated with stromal reaction in patients with gastric cancer.
    Shen KH; Chi CW; Lo SS; Kao HL; Lui WY; Wu CW
    Anticancer Res; 2000; 20(2B):1307-10. PubMed ID: 10810440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer.
    Endo K; Maehara Y; Baba H; Yamamoto M; Tomisaki S; Watanabe A; Kakeji Y; Sugimachi K
    Anticancer Res; 1997; 17(3C):2253-8. PubMed ID: 9216697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.
    Waas ET; Wobbes T; Ruers T; Lomme RM; Hendriks T
    Eur J Surg Oncol; 2006 Sep; 32(7):756-63. PubMed ID: 16650961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of transforming growth factor beta1 are significantly correlated with venous invasion in patients with gastric cancer.
    Lin Y; Kikuchi S; Obata Y; Yagyu K;
    J Gastroenterol Hepatol; 2006 Feb; 21(2):432-7. PubMed ID: 16509870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma.
    Patel BP; Shah PM; Rawal UM; Desai AA; Shah SV; Rawal RM; Patel PS
    J Surg Oncol; 2005 May; 90(2):81-8. PubMed ID: 15844188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients.
    Mroczko B; Kozłowski M; Groblewska M; Łukaszewicz M; Nikliński J; Jelski W; Laudański J; Chyczewski L; Szmitkowski M
    Clin Chim Acta; 2008 Mar; 389(1-2):61-6. PubMed ID: 18155162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
    Sliwowska I; Kopczyński Z
    Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer.
    Hrabec E; Strek M; Nowak D; Hrabec Z
    Respir Med; 2001 Jan; 95(1):1-4. PubMed ID: 11207010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation of preoperative plasma levels of big endothelin-1 to prognosis of gastric carcinoma].
    Teng XJ; Liu R; Zhang ZX; He JF; Shen ZX
    Ai Zheng; 2008 Jan; 27(1):88-91. PubMed ID: 18184472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer.
    Aung PP; Oue N; Mitani Y; Nakayama H; Yoshida K; Noguchi T; Bosserhoff AK; Yasui W
    Oncogene; 2006 Apr; 25(17):2546-57. PubMed ID: 16331256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of changes in tumor markers, extracellular matrix, MMP-9 and VEGF in patients with gastric carcinoma.
    Gao ZL; Zhang C; Du GY; Lu ZJ
    Hepatogastroenterology; 2007; 54(77):1591-5. PubMed ID: 17708308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer.
    Leppä S; Saarto T; Vehmanen L; Blomqvist C; Elomaa I
    Breast Cancer Res Treat; 2005 Mar; 90(2):117-25. PubMed ID: 15803358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.